Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;12(4):255-259.
doi: 10.1159/000471759. Epub 2017 Aug 29.

A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction

Mohammed Osman  1 , Mohammad Elkady  2
Affiliations

A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction

Mohammed Osman et al. Breast Care (Basel). 2017 Sep.

Abstract

Background: The primary objective of the study was to evaluate the long-term changes in ejection fraction (EF) associated with paclitaxel infusion.

Methods: 50 patients were enrolled in this prospective study between 2011 and 2015. The study design included frequent follow-up visits to the clinic, EF evaluation at baseline, and regular EF assessment by echocardiography for 30 months after treatment.

Results: The median baseline EF was 60% (95% confidence interval (CI) 50-80%). At 30 months, the median EF was 48% (95% CI 40-60%; p = 0.03). During the 30-month follow-up, 10 (20%) patients developed grade 1 and 2 cardiotoxicities; none developed grade 3 or 4 cardiotoxicities. Furthermore, paclitaxel cardiotoxicity increased among patients with high-risk features including associated diabetes mellitus, hypertension, prior radiotherapy to the chest wall, performance status of 2, and age > 60 years.

Conclusion: Paclitaxel has cardiotoxic effects. Careful monitoring of cardiac function during and after paclitaxel infusion is required in patients with high-risk features.

Keywords: CHF; Cardiotoxicity; EF; Echocardiography; Paclitaxel.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Design of the current trial.
Fig. 2
Fig. 2
Changes in median ejection fraction (EF) over time.
See this image and copyright information in PMC

References

    1. National cancer institute dtp.nci.nih.gov/timeline/flash/success_stories/S2_taxol.htm.
    1. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst. 1995;87:1169–1175. - PubMed
    1. Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol. 2002;53:508–518. - PMC - PubMed
    1. Clin-Info: e-Compendium of Pharmaceuticals and Specialties. www.pharmacists.ca/products-services/compendium-of-pharmaceuticals-and-s....
    1. Niederhuber JE. Global Cancer Control: An Essential Duty. NCI Cancer Bulletin, NCI; 2009.

LinkOut - more resources